Summary
Cytotoxic T lymphocytes (CTL), CD3+, α/β T-cell-receptor-positive, are important effector cells with specific immunity in melanoma patients. The establishment and expansion in vitro of CTL of a specific phenotype to tumor cells strongly depends on the method of activation and sensitization with tumor cells. We generated CD3+ CTL lines to melanoma by co-culturing peripheral blood lymphocytes with autologous irradiated melanoma cells and repetitive stimulation with high-dose interleukin-4 in a “cocktail” culture medium. CTL lines were investigated for their specificity to kill autologous and allogeneic melanoma. Histocompatibility locus antigen (HLA) class I (A, B) molecules are important restrictive recognition antigens for CTL. Although these antigens are highly polymorphic, they can share a similar immunogenic molecular epitope(s) and can be immunologically cross-reactive. The CTL lines generated were found to kill not only autologous melanoma, but also allogeneic melanomas having class I HLA-A antigens shared or “cross-reactive” with autologous HLA-A. These CTL lines were poor killers of melanomas bearing non-shared or non-cross-reactive HLA-A. Cold-target inhibition assays demonstrated this CTL cross-reactivity to allogeneic melanoma specificity. Epstein-Barr-virus-transformed autologous and allogeneic B lymphoblastoid cell lines failed to block autologous melanoma killing, indicating that CTL were not recognizing major histocompatibility complex antigens, serum proteins or culture medium products as the primary target antigen. HLA-A2 was the major shared HLA-A antigen recognized by CTL lines on the melanoma lines studied. CTL lines also recognized shared HLA-A11 and A24 on allogeneic melanoma. There were no CTL lines showing restriction to HLA-B. These results suggest that common tumor-associated antigens are present on melanomas and are recognized in association with distinct HLA-A epitopes by CTL.
This is a preview of subscription content, log in via an institution to check access.
References
Ando I, Hoon DSB, Suzuki Y, Golub SH, Irie RF (1987) Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. Int J Cancer 40: 12
Anichini A, Mazzocchi A, Fossati G, Parmiani G (1989) Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 142: 3692
Barbetti A, Park MS, Terasaki PI, Clark B, Fan J-L (1989) HLA serologic epitopes: In: Clinical transplants. UCLA Tissue Typing Laboratory, Los Angeles, p 477
Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329: 512
Crowley NJ, Slingluff CL, Darrow TL, Seigler HF (1990) Generation of human autologous melanoma-specific cytotoxic T cells using HLA-A2-matched allogeneic melanoma. Cancer Res 50: 492
Davis MM, Bjorkman PJ (1988) T-cell antigen receptor genes and T-cell recognition. Nature 334: 395
Foshag LJ, Hoon DSB, Okun E, Nizze A, Morton DL (1990) HLA class I antigen expression by melanoma and the immune response in patients with allogeneic immunization. Proc Am Assoc Cancer Res 31: 281
Hancock GE, Cohn ZA, Kaplan G (1989) The generation of antigenspecific major histocompatibility complex-restricted cytotoxic T lymphocytes of CD4+ phenotype. Enhancement by the cutaneous administration of interleukin 2. J Exp Med 169: 909.
Hoon DSB, Ando I, Sviland G, Tsuchida T, Okun E, Morton DL, Irie RF (1989) Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. Int J Cancer 43: 857
Hoon DSB, Foshag LJ, Nizze AJ, Bohman R, Morton DL (1990) Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 50: 5358
Irie RF, Sze LL, Saxton RE (1982) Human antibody to OFA-1, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines. Proc Natl Acad Sci USA 79: 5666
Kourilsky P, Claverie J-M (1989) MHC-antigen interaction: what does the T cell receptor see? Adv Immunol 45: 107
Morton DL, Hoon DSB, Gupta RG, Nizze AJ, Famatiga E, Foshag LJ, Furutani S, Irie RF (1989) Treatment of malignant melanoma by active specific immunotherapy in combination with biological response modifiers: In: Toriso M, Yoshida T (eds) New horizons of tumor immunotherapy. Elsevier, Amsterdam, p 665
Morton DL, Foshag LJ, Nizze A, Gupta RK, Famatiga E, Hoon DSB, Irie RF (1989) Active specific immunotherapy in surgical oncology. Semin Surg Oncol 5: 420
Morton DL, Hoon DSB, Foshag LJ, Nizze A, Gupta RK, Famatiga E, Irie RF (1991) Active immunotherapy of metastatic melanoma with melanoma vaccine and immunomodulation. Proc Am Assoc Cancer Res 32: 492
Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma: I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136: 1888
Paliard X, de Waal Malefijt R, de Vries JE, Spits H (1988) Interleukin-4 mediates CD8 induction on human CD4+ T cell clones. Nature 335: 642
Paliard X, Yssel H, Blanchard D, Waitz JA, de Vries JE, Spits H (1989) Antigen specific and MHC nonrestricted cytotoxicity of T cell receptor αβ+ and τδ+ human T cell clones isolated in IL-4. J Immunol 143: 452
Park MS, Terasaki PI, Barbetti A, Han H, Cecka JM (1988) Significance of HLA molecular structure to transplantation. In: Clinical transplants. UCLA Tissue Typing Laboratory, Los Angeles p 301
Parmiani G, Anichini A, Fossati G (1990) Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82: 361
Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ (1986) Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas: I. Development, phenotype, and specificity. J Immunol 137: 3042
Spits H, Yssel H, Paliard X, Kastelein R, Figdor C, de Vries JE (1988) Interleukin-4 inhibits interleukin-2 mediated induction of human lymphokine activated killer cells, but not the generation of antigen specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 141: 29
Topalian SL, Solomon D, Rosenberg SA (1989) Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714
Van Rood JJ, Claas FHJ (1990) The influence of allogeneic cells on the human T and B cell repertoire. Science 248: 1388
Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A (1989) Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170: 797
Yamamoto S, Hoon DSB, Chandler P, Schmid I, Irie RF (1990) Generation of lymphokine-activated killer cell activity by low dose recombinant interleukin-2 and tumor cells. Cell Immunol 128: 515
Yoshikai Y, Kimura N, Toyonaga B, Mak TW (1986) Sequences and repertoire of human T cell receptor α chain variable region genes in mature T lymphocytes. J Exp Med 164: 90
Zinkernagel RM, Doherty PC (1974) Restriction of in vivo T cell-mediated cytotoxicity in lymphocyte choriomeningitis within a syngeneic or semi allogeneic system. Nature 248: 701
Author information
Authors and Affiliations
Additional information
This study was supported by grant CA12 582 awarded by the National Cancer Institute, USA
Rights and permissions
About this article
Cite this article
Hayashi, Y., Hoon, D.S.B., Park, M.S. et al. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. Cancer Immunol Immunother 34, 419–423 (1992). https://doi.org/10.1007/BF01741754
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741754